The human study will evaluate the Company’s proprietary psilocybin drug (NM-1001) in the treatment of Fragile X Syndrome Vancouver, British Columbia–(Newsfile Corp. – December 22, 2022) – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) […]
Microdose Treatment Modulates Cognition Vancouver, British Columbia— December 8, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and […]
Microdose Psilocybin Safety and Efficacy Clinical Study in Fragile X Syndrome Vancouver, British Columbia– November 30, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and […]
NEXT SUPER STOCK: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA) CMO Marvin Hausman, M.D.: “Nova’s Psilocybin-based Therapeutics Showing Vast Potential for Autism and Other Neuroinflammatory Disorders” 9/7/22 NEXT SUPER STOCK: Nova Mentis Life Sciences […]
Vancouver, British Columbia-November 17, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (OTCQB: NMLSF) (FSE: HN3Q) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders […]
Company Plans to Submit Clinical Trial Application in Canada Vancouver, British Columbia— September 15, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader […]
– Alakin to be utilized in a Parkinson study set to commence in Paris, France – TORONTO, ON / August 2, 2022 / AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company committed to acquiring and advancing Artificial Intelligence/Machine […]
Vancouver, British Columbia- – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased […]
11 of 17 patients (64.7%) achieved an overall renal response of 50% or greater reduction in urine protein to creatinine ratio (UPCR) at 6 months 6 of 17 patients (35.2%) achieved a complete renal response, including a […]
Vancouver, British Columbia–June 22, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders […]
TORONTO, ON / June 22, 2022 / AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, is pleased to announce that its minority-owned subsidiary, Tech2Heal […]
Results show that oral cepharanthine plus paclitaxel (combination therapy) significantly reduced tumor volume and increased tumor growth inhibition at day 28, the final day of dosing compared to paclitaxel alone (p=0.0049) Dose range finding demonstrates […]
Vancouver, British Columbia–(Newsfile Corp. – June 9, 2022) – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics […]
SBT-272 improved neuronal health, superior to other approved and investigational agents Phase 1 study to evaluate safety and tolerability of SBT-272 in healthy volunteers is underway BOSTON, June 8, 2022 — Stealth BioTherapeutics Corp (NASDAQ: MITO), […]
Novavax COVID-19 vaccine receives positive vote from U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee If Emergency Use Authorization is granted by the FDA, the Novavax COVID-19 vaccine would become the […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
